Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PAVmed Inc PAVMZ


Primary Symbol: PAVM

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device... see more

Recent & Breaking News (NDAQ:PAVM)

ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors

GlobeNewswire June 15, 2020

PAVmed Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard(TM) Esophageal DNA Test

GlobeNewswire June 11, 2020

PAVmed Collaborates with Canon on DisappEAR(TM) Pediatric Ear Tubes

GlobeNewswire June 3, 2020

PAVmed Reports Preliminary First Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire May 21, 2020

PAVmed to Hold Business Update Conference Call on May 21, 2020

GlobeNewswire May 11, 2020

PAVmed Receives FDA 510(k) Clearance for its CarpX(TM) Minimally Invasive Carpal Tunnel Device

GlobeNewswire April 21, 2020

PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update

GlobeNewswire April 9, 2020

PAVmed Subsidiary Lucid Diagnostics' EsoCheck Esophageal Cell Collection Device Receives Prestigious Edison Best New Product Award

GlobeNewswire April 2, 2020

PAVmed Receives $6.3 Million in Gross Proceeds from Completion of November 2019 Financing

GlobeNewswire March 31, 2020

PAVmed to Hold Business Update Conference Call on April 9, 2020

GlobeNewswire March 24, 2020

PAVmed Announces FDA 510(k) Re-submission for its CarpX(TM) Minimally Invasive Carpal Tunnel Device

GlobeNewswire March 9, 2020

PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck(TM) in Eosinophilic Esophagitis (EoE) Patients

GlobeNewswire March 2, 2020

PAVmed Subsidiary Lucid Diagnostics Partners with Fred Hutchinson Cancer Research Center to Evaluate Barrett's Esophagus (BE) Progression Biomarkers Using EsoCheck(TM)

GlobeNewswire February 20, 2020

PAVmed Adds EsoCure(TM) Esophageal Ablation Device with Patented Caldus(TM) Technology to Commercial Product Pipeline

GlobeNewswire February 18, 2020

U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test

GlobeNewswire February 11, 2020

PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance

GlobeNewswire January 13, 2020

PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test

GlobeNewswire December 19, 2019

PAVmed Provides Update on CarpX(TM) Clinical Safety Study

GlobeNewswire December 13, 2019

PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update

GlobeNewswire November 21, 2019

PAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic Products

GlobeNewswire November 14, 2019